Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab

por Kretsos, K, Jullion, A, Zamacona, M, Harari, O, Shaw, S, Boulanger, B, Oliver, R
Publicado 2014

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients

por Lu, P, Hsu, J, Keane, C, Fettner, S, Wang, J, Ruperto, N, Harari, O, Brunner, HI, De Benedetti, F
Publicado 2013

PReS-FINAL-2188: Insulin sensitivity is improved in sjia children with insulin resistance after tocilizumab treatment: results from the tender study

por Mirjafari, H, Ruperto, N, Brunner, HI, Zuber, Z, Zulian, F, Maldonado-Velázquez, MR, Mantzourani, E, Murray, K, Roth, J, Rovensky, J, Vougiouka, O, Wang, J, Harari, O, Lovell, D, Martini, A, De Benedetti, F
Publicado 2013